| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/25/2014 | CA2544949C Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| 02/25/2014 | CA2542396C Fish protein hydrolyzate |
| 02/25/2014 | CA2541944C Microparticles comprising somatostatin analogues |
| 02/25/2014 | CA2532869C Novel peptidic conjugates for alopecia preventive and curative treatment |
| 02/25/2014 | CA2507936C Prion protein ligands and methods of use |
| 02/25/2014 | CA2476589C Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
| 02/25/2014 | CA2471879C Pharmaceutical composition containing ghrelin |
| 02/25/2014 | CA2451310C Antimicrobial peptides |
| 02/25/2014 | CA2207252C Inhibitors of prenyl transferases |
| 02/20/2014 | WO2014028861A1 Detection of high risk drusen |
| 02/20/2014 | WO2014028768A2 Evaluation of duf1220 copy number and methods of using the same |
| 02/20/2014 | WO2014028694A1 Methods and compositions for enhancing intranasal delivery of therapeutic agents |
| 02/20/2014 | WO2014028585A1 Compositions for targeted anti-aging therapy |
| 02/20/2014 | WO2014028560A2 T-cell redirecting bispecific antibodies for treatment of disease |
| 02/20/2014 | WO2014028545A1 Methods of preparing tecovirimat |
| 02/20/2014 | WO2014028461A2 Treatment and diagnosis of melanoma |
| 02/20/2014 | WO2014028087A1 Liposomal formulations of polymyxin and uses thereof |
| 02/20/2014 | WO2014028059A1 Rac1 inhibitors for the treatment of alport glomerular disease |
| 02/20/2014 | WO2014028011A1 Anti-microbial activity of synthetic peptides |
| 02/20/2014 | WO2014027958A1 Anti-viral methods and the use of an anti-viral agent |
| 02/20/2014 | WO2014027789A1 Interferon-alpha fusion protein in which cytoplasmic transduction peptide and polyethylene glycol are bonded to one another |
| 02/20/2014 | WO2014027668A1 Reelin decomposition using adamts-3 |
| 02/20/2014 | WO2014027608A1 Brown adipocyte differentiation-inducing agent |
| 02/20/2014 | WO2014027363A1 A growth factor concentrate for treating hair loss |
| 02/20/2014 | WO2014027362A1 A method of preparing a growth factor concentrate derived from human platelets |
| 02/20/2014 | WO2014027361A1 A growth factor concentrate for treating periorbital hyperpigmentation |
| 02/20/2014 | WO2014027360A1 A growth factor concentrate for treating facial wrinkles |
| 02/20/2014 | WO2014027359A1 A growth factor concentrate for treating tendinopathies |
| 02/20/2014 | WO2014027254A1 Pharmaceutical microparticulate compositions of polypeptides |
| 02/20/2014 | WO2014027253A1 Pharmaceutical microparticulate compositions of polypeptides |
| 02/20/2014 | WO2014027087A1 METHODS OF USING THE CALCINEURIN A VARIANT CNAß1 FOR THE TREATMENT OF CARDIAC HYPERTROPHY |
| 02/20/2014 | WO2014027049A1 Therapeutic uses of dogfish glucagon and analogues thereof |
| 02/20/2014 | WO2014027012A1 Method for producing a composition for treating a tooth lesion |
| 02/20/2014 | WO2014026282A1 Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors |
| 02/20/2014 | WO2014001956A3 Combinational use of pegylated recombinant human arginase with chemotherapeutic/target therapeutic drug in cancer treatment |
| 02/20/2014 | WO2013179264A8 Use of compounds that selectively modulate astrocytic release of substances through hemichannels of connexins and pannexins, without influencing gap junctions, for the treatment of psychiatric disorders |
| 02/20/2014 | WO2013173417A3 Glucokinase activator compositions for the treatment of diabetes |
| 02/20/2014 | WO2013136189A3 Methods and materials for treatment of pompe's disease |
| 02/20/2014 | WO2012142320A8 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| 02/20/2014 | US20140051644 Pharmaceutical composition for treating hyperproliferative diseases |
| 02/20/2014 | US20140051642 Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) |
| 02/20/2014 | US20140051641 Compounds for enzyme inhibition |
| 02/20/2014 | US20140051639 Compositions and Methods which modulate G-Protein Signaling for the Treatment of Inflammatory Disorders such as Asthma and Allergic Conjunctivitis |
| 02/20/2014 | US20140051638 Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
| 02/20/2014 | US20140051634 Pharmaceutical combined preparation containing a therapeutic protein |
| 02/20/2014 | US20140051632 Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents |
| 02/20/2014 | US20140051631 Pharmaceutical composition comprising tpo or an agonist of the tpo receptor |
| 02/20/2014 | US20140051625 Bone Targeted Therapeutics and Methods of Making and Using the Same |
| 02/20/2014 | US20140051624 Oxidant resistant apolipoprotein a-1 and mimetic peptides |
| 02/20/2014 | US20140051166 Method and medicament for inhibiting the expression of a given gene |
| 02/20/2014 | US20140051145 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| 02/20/2014 | US20140051096 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| 02/20/2014 | US20140050793 Novel Compositions for Inhibiting Virus Entry and Promoting Virolysis, and Methods Thereof |
| 02/20/2014 | US20140050781 Use of AGR3 for Treating Cancer |
| 02/20/2014 | US20140050777 Liposomal Formulations of Polymyxin and Uses Thereof |
| 02/20/2014 | US20140050773 Compound comprising alpha-msh for use in endodontic regeneration |
| 02/20/2014 | US20140050771 Pdgf induced cell homing |
| 02/20/2014 | US20140050746 Auristatin drug linker conjugates |
| 02/20/2014 | US20140050739 Local complement inhibition for treatment of complement-mediated disorders |
| 02/20/2014 | US20140050737 Compounds for enzyme inhibition |
| 02/20/2014 | US20140050728 Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications |
| 02/20/2014 | US20140050715 Protein hydrolysates as agents for overcoming addiction |
| 02/20/2014 | US20140050714 Use of hsp70 as a regulator of enzymatic activity |
| 02/20/2014 | US20140050700 EX-VIVO TREATMENT OF PERIPHERAL BLOOD LEUKOCYTES WITH IFN-Lambda |
| 02/20/2014 | US20140050697 Analysis of hcv genotypes |
| 02/20/2014 | US20140050666 Scavenger receptor uptake for fabry disease enzyme replacement therapy |
| 02/20/2014 | US20140050660 T-Cell Redirecting Bispecific Antibodies for Treatment of Disease |
| 02/20/2014 | CA2874864A1 T-cell redirecting bispecific antibodies for treatment of disease |
| 02/19/2014 | EP2698635A2 Methods and compositions for targeting sites of neovascular growth |
| 02/19/2014 | EP2698386A1 Fusion protein |
| 02/19/2014 | EP2698378A1 Anticoagulant polypeptide and applications thereof |
| 02/19/2014 | EP2698376A1 Cancer-targeting peptides and uses thereof in cancer therapy |
| 02/19/2014 | EP2698163A1 Codon-optimized factor VIII variants and synthetic liver-specific promoter |
| 02/19/2014 | EP2698162A1 Method for producing a composition for treating a tooth lesion |
| 02/19/2014 | EP2698153A1 Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase II detoxification enzymes |
| 02/19/2014 | EP2697654A1 Method for determining the risk of cardiovascular events using igfbp fragments |
| 02/19/2014 | EP2697389A1 Osteoblast-expressed lipocalin 2 regulates glucose metabolism |
| 02/19/2014 | EP2697371A1 Derivative of the lactobacilus johnsonii strain cncm i-1225, deficient in d-lactic acid production and with an improved shelf life |
| 02/19/2014 | EP2697254A2 Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9 |
| 02/19/2014 | EP2697253A1 Therapeutic peptides and use thereof against huntington's disease |
| 02/19/2014 | EP2697241A2 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment |
| 02/19/2014 | EP2696890A1 Treatment of microbial infections |
| 02/19/2014 | EP2696889A1 Variants of human gdnf |
| 02/19/2014 | EP2696888A2 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| 02/19/2014 | EP2696887A2 Redox responsive polymeric nanocapsules for protein delivery |
| 02/19/2014 | EP2696886A2 C1q/tnf-related protein 12 and compositions and methods of using same |
| 02/19/2014 | EP2696885A1 Methods for chronic pain management and treatment using hcg |
| 02/19/2014 | EP2696884A2 Long-acting peptide analogs |
| 02/19/2014 | EP2696883A1 Treatment of hepatitis c virus infection with alisporivir |
| 02/19/2014 | EP2696882A1 Pharmaceutical composition |
| 02/19/2014 | EP2696875A1 Methods for treating bacterial infection |
| 02/19/2014 | EP2696856A1 Controlled-release formulation comprising hcg |
| 02/19/2014 | EP2696852A1 System and method for multiphasic release of growth factors |
| 02/19/2014 | EP2696847A1 Fatty acid acylated amino acids for oral peptide delivery |
| 02/19/2014 | EP2696687A1 Double-acylated glp-1 derivatives |
| 02/19/2014 | CN1350592B Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms |
| 02/19/2014 | CN103596595A Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate |
| 02/19/2014 | CN103596592A Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-ErbB3 agents |
| 02/19/2014 | CN103596584A Multi-substituted insulins |
| 02/19/2014 | CN103596583A Novel glucagon analogues |